| Acute lymphocytic leukemia

Asparlas vs Rylaze

Side-by-side clinical, coverage, and cost comparison for acute lymphocytic leukemia.

Deep comparison between: Asparlas vs Rylaze with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRylaze has a higher rate of injection site reactions vs Asparlas based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Rylaze but not Asparlas, including UnitedHealthcare

Category

Asparlas

Rylaze

At A Glance

RouteIV infusion

FrequencyEvery 21 days

ClassPegylated L-asparaginase

RouteIM injection

FrequencyEvery 48 hours

ClassRecombinant L-asparaginase

Indications

Acute lymphocytic leukemia

Acute lymphocytic leukemia
Precursor cell lymphoblastic lymphoma

Dosing

Acute lymphocytic leukemia 2,500 units/m2 intravenously no more frequently than every 21 days.

Acute lymphocytic leukemia, Precursor cell lymphoblastic lymphoma 25 mg/m2 IM every 48 hours, or 25 mg/m2 IM on Monday and Wednesday mornings and 50 mg/m2 IM on Friday afternoon, as replacement for a long-acting asparaginase product; premedicate with acetaminophen, H-1 blocker, and H-2 blocker 30-60 minutes prior to administration.

Contraindications

History of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase therapy
History of serious pancreatitis during previous L-asparaginase therapy
History of serious thrombosis during previous L-asparaginase therapy
History of serious hemorrhagic events during previous L-asparaginase therapy
Severe hepatic impairment

History of serious hypersensitivity reactions to Erwinia asparaginase, including anaphylaxis
History of serious pancreatitis during previous asparaginase therapy
History of serious thrombosis during previous asparaginase therapy
History of serious hemorrhagic events during previous asparaginase therapy
Severe hepatic impairment

Drug Interactions

41View drug interactions

848View drug interactions

Adverse Reactions

Most common Elevated transaminase, bilirubin increased, pancreatitis, abnormal clotting studies, diarrhea, hypersensitivity, embolic and thrombotic events, sepsis, dyspnea, hemorrhages, fungal infection, pneumonia, arrhythmia, cardiac failure

Serious Hypersensitivity, pancreatitis, thrombosis, hemorrhage, hepatotoxicity including veno-occlusive disease

Postmarketing Veno-occlusive disease (hepatic)

Most common (>20%) Abnormal liver test, nausea, musculoskeletal pain, infection, fatigue, headache, febrile neutropenia, pyrexia, hemorrhage, stomatitis, abdominal pain, decreased appetite, drug hypersensitivity, hyperglycemia, diarrhea, pancreatitis, hypokalemia

Serious Febrile neutropenia, infection, drug hypersensitivity, pyrexia, nausea, dehydration, stomatitis, acute kidney injury, pancreatitis, diarrhea, viral infection

Postmarketing Veno-occlusive disease (VOD)

Pharmacology

Pegylated L-asparaginase enzyme that depletes plasma asparagine by catalyzing its conversion to aspartic acid and ammonia; leukemic cells with low asparagine synthetase expression depend on exogenous asparagine for survival and are killed by its depletion.

Asparaginase erwinia chrysanthemi (recombinant)-rywn is a recombinant bacterial enzyme that catalyzes the conversion of L-asparagine to aspartic acid and ammonia, depleting plasma asparagine and killing leukemic cells that depend on exogenous asparagine for survival due to low asparagine synthetase expression.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Asparlas